Circulating mesenchymal stem cells, stromal derived factor (SDF)-1 and IP-10 levels increased in clinically active Multiple Sclerosis patients but not in clinically stable patients treated with beta Interferon

ConclusionCirculating MSCs, IP-10 and SDF-1α levels, increased in RRMS patients with clinically active not on DMT and IFN-β therapy reduced circulating MSCs and SDF-1α levels.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research